Skip to Main Content

For further information, see CMDT Part 15-05: Sideroblastic Anemia

KEY FEATURES

  • Presence of ringed sideroblasts in the bone marrow

  • Elevated serum iron levels and transferrin saturation

  • Heterogeneous group of disorders in which reduced hemoglobin synthesis occurs because of

    • Reduced ability to synthesize heme due to

    • An impaired ability to incorporate iron into protoporphyrin IX

  • Iron accumulates, particularly in mitochondria

  • Modern classification divides sideroblastic anemia into two categories

    • Dyserythropoiesis (ie, hypohepcidinemia)

    • Transfusion-dependent, eg

      • Myelodysplastic neoplasms

      • Thalassemia

  • Most often it is a subtype of myelodysplastic neoplasms

  • Other causes include

    • Chronic alcohol use disorder

    • Lead poisoning

      Copper deficiency (hypocupremia)

    • Medications

      • Isoniazid

      • Chloramphenicol

    • Chronic infection or inflammation

  • Inherited forms are usually X-linked but rare recessive forms have been documented

CLINICAL FINDINGS

  • Symptoms of anemia; no other specific clinical features

  • In hypocupremia (copper deficiency), myelopathy or demyelinating peripheral neuropathy in some patients

DIAGNOSIS

  • Anemia usually moderate, hematocrit 20–30%

  • Mean corpuscular volume (MCV)

    • Usually normal or slightly increased in sideroblastic subtype of myelodysplastic neoplasms

    • Usually low in other subtypes

      • Especially inherited forms

      • Leading to confusion with iron deficiency

  • Peripheral blood smear characteristically shows

    • Dimorphic population of red blood cells

    • One normal and one hypochromic

  • In cases of lead poisoning

    • Coarse basophilic stippling of red blood cells

    • Elevated serum lead level

  • Bone marrow iron stain shows

    • Generalized increase in iron stores

    • Ringed sideroblasts

      • Red blood cells with iron deposits in mitochondria

      • Encircling the nucleus

    • Marked erythroid hyperplasia resulting from ineffective erythropoiesis

      • Expansion of erythroid compartment of bone marrow

      • Without release of adequate mature red blood cells into peripheral blood

  • Serum iron level and transferrin saturation are high

  • In hypocupremia

    • Normocytic anemia in two-thirds of cases; macrocytic in remainder

    • Zinc level is often elevated due to

      • Zinc-imbedded dental fillings

      • Excessive oral zinc intake

      • Gastric bypass surgery

    • Neutropenia or thrombocytopenia may be present

    • Bone marrow biopsy

      • Usually interpreted as "myelodysplastic syndrome" due to the presence of ringed sideroblasts and vacuolization of the myeloid and erythroid progenitors

TREATMENT

  • Occasionally, red blood cell transfusion is required for severe anemia

  • Recombinant erythropoietin therapy is not usually effective

  • Oral pyridoxine (50–200 mg/day) occasionally useful

  • Removal of offending toxins and drugs is needed in the secondary acquired forms

  • Luspatercept

    • FDA approved for myelodysplastic neoplasms with ringed sideroblasts

    • It is a TGF-β ligand trap

    • Promotes erythroid maturation

    • Reduces need for transfusion

  • Hypocupremia

    • Administer copper sulfate (2.5 mg orally twice daily)

    • Associated with high hematologic response rate but low neurologic response rate

    • Exogenous or endogenous zinc exposure needs to be eliminated

  • Refer to hematologist if diagnostic or transfusion support is needed.

Pop-up div Successfully Displayed

This div only appears when the trigger link is hovered over. Otherwise it is hidden from view.

  • Create a Free Profile